Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268

Summary

This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.

Timeline

Start

2024-05-15

Primary completion

2024-11-01

Completion

2024-11-01

Drugs

Indications